Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European
Commission has granted marketing authorization for Harvoni ®
(ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet
regimen to treat the majority of chronic hepatitis C genotype 1 and 4
infection in adults.
for European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 investment picks